Chronic Kidney Failure Clinical Trial
Official title:
A Randomized, Controlled, Open-label, Parallel, Multicenter Study in Kidney Failure Patients on Hemodialysis Comparing the Theranova Dialyzer to Hemodiafiltration
Traditional HD therapy is very effective in clearing urea and smaller middle molecules, but is limited in clearing larger middle molecules. These accumulated large middle-molecular-weight uremic toxins may cause and aggravate inflammation, atherosclerosis and calcification, which indirectly lead to the death of patients. Studies have shown that, compared to conventional high-flux HD (HF-HD), HDF that combines diffusion and convection can reduce the all-cause mortality. Compared to the conventional HF-HD, HDF can more effectively clear larger molecular toxins in one session, which may be related to the better clearance effect of HDF on middle-molecular-weight toxins Theranova's innovative Medium Cut-Off® membranes has high permeability and selectivity to uremic toxins (clearance of a molecular weight of up to 45 kDa) and can retain essential proteins, to maintain patient's albumin level during the HD treatment[9]. Its unique membrane and high cut-off characteristics expand the clearance range beyond those of flux membrane dialyzers. Theranova 400 can be widely used in most blood purification centers under conventional HD equipment and treatment modes, with the effect similar to HDF This study is to demonstrate non-inferiority of the Theranova 400 Dialyzer in hemodialysis (HD) mode (hereinafter referred to as Theranova 400) compared to hemodiafiltration (HDF), using FX 800 in HDF mode (hereinafter referred to as FX 800).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06216015 -
Exercise Training and Kidney Transplantation
|
N/A | |
| Completed |
NCT00781690 -
Reduction of Heparin Dose in Dialysis With Evodial System
|
N/A | |
| Completed |
NCT00806130 -
Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients
|
||
| Completed |
NCT00153621 -
Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients
|
N/A | |
| Completed |
NCT06165211 -
Nature-Based Sound Application For Hemodialysis Patients
|
N/A | |
| Not yet recruiting |
NCT04013620 -
CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction
|
Phase 3 | |
| Withdrawn |
NCT03998917 -
Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis.
|
||
| Completed |
NCT02586376 -
Effects of the Low-level Laser Therapy (LLLT) on Muscle Strength (MS) of the Patients With Kidneys Failure (KF)
|
N/A | |
| Completed |
NCT00794326 -
Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD
|
Phase 3 | |
| Completed |
NCT05185999 -
Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients
|
Phase 1 | |
| Completed |
NCT03076528 -
An Innovative Virtually Supervised Exercise for Dialysis Patients
|
Phase 2 | |
| Completed |
NCT02513303 -
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
|
Phase 3 | |
| Completed |
NCT00804453 -
Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line
|
N/A | |
| Unknown status |
NCT00788905 -
Comparison of Conventional Dialysis and the Allient System
|
N/A | |
| Completed |
NCT01085552 -
Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects
|
Phase 1 | |
| Completed |
NCT00694824 -
Vascular Calcification's Risk Factors in Haemodialysis Patients
|
||
| Completed |
NCT00074620 -
A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis
|
Phase 2 | |
| Withdrawn |
NCT06030050 -
Animal Assisted Intervention for Hemodialysis Outpatients
|
N/A | |
| Not yet recruiting |
NCT05562869 -
Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
|
Phase 3 | |
| Completed |
NCT03437538 -
Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter
|
N/A |